Raltitrexed

CHEMBL225071 Phase 4 ได้รับการอนุมัติ Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

458.5 g/mol

LogP

1.4

Phase

4

Raltitrexed is a quinazoline folate analog that directly and specifically inhibits thymidylate synthase (TS) after intracellular polyglutamation, thereby depleting thymidine monophosphate and disrupting DNA synthesis and repair in rapidly dividing cells. It is used for the treatment of advanced colorectal cancer and has been investigated in mesothelioma and other malignancies.

น้ำหนักโมเลกุล

458.5000 g/mol

LogP

1.40

TPSA

177.00 Å²

Lipinski RO5

ผ่าน

ด้านการรักษา

Pancreatic Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nc(=O)c2cc(CN(C)c3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)ccc2[nH]1

InChI

InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1

Molecular Formula

C21H22N4O6S

HBD / HBA

4 / 9

พันธะที่หมุนได้

9

อะตอมหนัก

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Raltitrexed is a quinazoline folate analog that directly and specifically inhibits thymidylate synthase (TS) after intracellular polyglutamation, thereby depleting thymidine monophosphate and disrupting DNA synthesis and repair in rapidly dividing cells. It is used for the treatment of advanced colorectal cancer and has been investigated in mesothelioma and other malignancies.

Yes, Raltitrexed is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL225071. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 135400182. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Raltitrexed บน PillFYI

โครงสร้าง

ข้อมูลด่วน

สูตร: C21H22N4O6S

ลิงก์ภายนอก

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.